Sweden's Integrum Q4 net sales fall
Sweden's Integrum Q4 net sales fall
Overview
Sweden bone-anchored prosthetics maker's fiscal Q4 net sales declined yr/yr
Operating profit impacted by SEK 15 mln in non-recurring items, mainly reclassification of inventory
Company performed record number of S1 surgeries, cost base continued to improve
Outlook
Integrum says it is better positioned for 2026/27 with a lower cost base
Company expects continued focus on commercialisation and patient flows in the US
Integrum sees rising activity and growing interest in osseointegration in priority markets
Result Drivers
RECORD S1 SURGERIES - Co said number of S1 surgeries performed reached highest level in its history, reflecting positive momentum in core business
COST BASE IMPROVEMENT - Underlying cost base continued to improve due to organisational changes and focus on efficiency
NON-RECURRING ITEMS - Operating profit impacted by SEK 15 mln in non-recurring items, mainly reclassification of inventory to property, plant and equipment, organisational changes and review of older receivables
Company press release: ID:nMFN4pn8q
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Adjusted EBIT |
| -SEK 5 mln |
|
Q4 EBIT |
| -SEK 20 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for Integrum AB is SEK32.58, about 315.6% above its June 3 closing price of SEK7.84
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 24 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)